bicalutamide
information and resources from the National Cancer Institute
NCI Thesaurus | bicalutamide
A synthetic, nonsteroidal antiandrogen. Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. NCI Thesaurus | bicalutamide
A synthetic, nonsteroidal antiandrogen. Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors.
|
|
|
|
news articles
Advances in Early-Stage Prostate Cancer Mar 6, 2006
Medscape (subscription) ...of 3 parallel clinical trials of men with either localized or locally advanced prostate cancer randomized to receive hormonal therapy with bicalutamide 150 mg ...
ASCO 2006 Prostate Cancer Symposium - Session on The Treatment of ... Mar 3, 2006
UroToday, Dr. See presented a podium abstract on adding bicalutamide 150mg to radiotherapy to significantly improve overall survival in men with locally advanced CaP.
Prostate Cancer: New choice for hormone refractory patients Dec 8, 2005
PharmaLive.com (press release), LONDON, December 8, 2005- While the use of AstraZeneca’s bicalutamide monotherapy in prostate cancer continues, its use has significantly decreased in ...
Sales of Major Players in the Prostrate Cancer Market have been ... Nov 21, 2005
PharmaLive.com (press release), Safety concerns with AstraZenecas Casodex (bicalutamide) have also seen a significant proportion of physicians switching to alternatives. ...
AstraZeneca's Casodex may get boost Dec 8, 2005
Science Daily (press release) ..."This will be especially important in the (United States), as certain oral medications including bicalutamide (Casodex) are expected to be reimbursable under ...
New Data Show Survival Benefit for Arimidex(TM) in Early Breast ... Dec 9, 2005
news aktuell (Pressemitteilung), ...oncology that led to the development of its current anti-cancer therapies including 'ARIMIDEX' (anastrozole), 'CASODEX' (bicalutamide), 'FASLODEX' (fulvestrant ...
AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005
PR Newswire (press release), ARIMIDEX(R) (anastrozole), ATACAND(R) (candesartan cilexetil), ATACAND HCT(R) (candesartan cilexetil-hydrochlorothiazide), CASODEX(R) (bicalutamide), CRESTOR(R ...
|
|
